Rep. Lisa C. McClain Purchases Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Key Points

• Representative Lisa C. McClain purchased between $1,001 and $15,000 in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) on June 17th, as disclosed in a filing.
• Roivant Sciences recently reported a net loss with an earnings per share of ($0.31), which missed analyst expectations of ($0.16).
• Goldman Sachs upgraded Roivant Sciences to a "strong-buy" rating with a target price of $19.00, amid a generally positive outlook from analysts.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Roivant Sciences Ltd. NASDAQ: ROIV. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Roivant Sciences stock on June 17th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Roivant Sciences Stock Performance

ROIV stock opened at $11.72 on Thursday. The stock has a market cap of $7.97 billion, a P/E ratio of -16.74 and a beta of 1.15. The firm has a 50 day simple moving average of $11.41 and a 200 day simple moving average of $10.91. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The company had revenue of $7.57 million for the quarter, compared to analyst estimates of $62.17 million. Roivant Sciences had a negative return on equity of 15.90% and a negative net margin of 2,111.79%.During the same quarter in the prior year, the business posted ($0.23) earnings per share. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on ROIV. The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price for the company in a research note on Thursday, July 10th. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, Roivant Sciences currently has an average rating of "Buy" and an average target price of $16.50.

Insiders Place Their Bets

In related news, COO Eric Venker sold 566,278 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16. Following the transaction, the chief operating officer owned 1,462,223 shares of the company's stock, valued at approximately $16,406,142.06. The trade was a 27.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the business's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the transaction, the insider directly owned 37,284,108 shares in the company, valued at $427,275,877.68. This trade represents a 1.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,090,503 shares of company stock worth $34,991,546 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in shares of Roivant Sciences by 16.3% in the first quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company's stock valued at $40,362,000 after purchasing an additional 560,641 shares during the period. GAMMA Investing LLC increased its position in Roivant Sciences by 83.0% during the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock worth $66,000 after acquiring an additional 2,945 shares during the period. Russell Investments Group Ltd. increased its position in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares during the period. UMB Bank n.a. increased its position in Roivant Sciences by 112.7% during the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after acquiring an additional 2,195 shares during the period. Finally, Bank of Montreal Can increased its position in Roivant Sciences by 20.2% during the fourth quarter. Bank of Montreal Can now owns 48,026 shares of the company's stock worth $568,000 after acquiring an additional 8,084 shares during the period. Institutional investors own 64.76% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.